Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 25Etoposide 23Cisplatin 16pembrolizumab 9Topotecan 9atezolizumab 7Pemetrexed 7Nivolumab 7Radiosurgery 6Irinotecan 5durvalumab 4Paclitaxel 4Gemcitabine 4Albumin-Bound Paclitaxel 4rovalpituzumab tesirine 3etoposide phosphate 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Cyclophosphamide 3vistusertib 2roniciclib 2pelcitoclax 2pazopanib 2epacadostat 2amrubicin 2Vorinostat 2Radiation 2Fluorodeoxyglucose F18 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Small Cell Lung Carcinoma × E-3810 × Clear all
NCT02109016 2019-07-29

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Clovis Oncology, Inc.

Phase 2 Terminated
18 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡